A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy
ABSTRACT Histologic transformation from non‐small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver and brain metastases during adjuvant atezolizumab therapy. The patient underwent a cra...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Thoracic Cancer |
| Subjects: | |
| Online Access: | https://doi.org/10.1111/1759-7714.15512 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576740906500096 |
|---|---|
| author | Nao Kobayashi Noriaki Sunaga Masakiyo Yatomi Ikuo Wakamatsu Sohei Muto Hayato Ikota Rei Yamaguchi Yoichi Ohtaki Toshiteru Nagashima Nobuteru Kubo Tomomi Masuda Yosuke Miura Hiroaki Tsurumaki Reiko Sakurai Yasuhiko Koga Takeshi Hisada Toshitaka Maeno |
| author_facet | Nao Kobayashi Noriaki Sunaga Masakiyo Yatomi Ikuo Wakamatsu Sohei Muto Hayato Ikota Rei Yamaguchi Yoichi Ohtaki Toshiteru Nagashima Nobuteru Kubo Tomomi Masuda Yosuke Miura Hiroaki Tsurumaki Reiko Sakurai Yasuhiko Koga Takeshi Hisada Toshitaka Maeno |
| author_sort | Nao Kobayashi |
| collection | DOAJ |
| description | ABSTRACT Histologic transformation from non‐small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver and brain metastases during adjuvant atezolizumab therapy. The patient underwent a craniotomy to resect a brain metastasis, which was pathologically diagnosed as SCLC. He subsequently received platinum‐based chemotherapy with durvalumab, resulting in sustained regression of the liver metastases. This case demonstrates a metastatic brain tumor‐acquired resistance to atezolizumab through histologic transformation from adenocarcinoma to SCLC. Therefore, rebiopsy is needed if recurrent disease appears during immune checkpoint inhibitor treatment in patients with non‐small cell lung cancer. |
| format | Article |
| id | doaj-art-223533b8458f46a8b552a1b86ec0393a |
| institution | Kabale University |
| issn | 1759-7706 1759-7714 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Thoracic Cancer |
| spelling | doaj-art-223533b8458f46a8b552a1b86ec0393a2025-01-30T22:40:34ZengWileyThoracic Cancer1759-77061759-77142025-01-01162n/an/a10.1111/1759-7714.15512A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab TherapyNao Kobayashi0Noriaki Sunaga1Masakiyo Yatomi2Ikuo Wakamatsu3Sohei Muto4Hayato Ikota5Rei Yamaguchi6Yoichi Ohtaki7Toshiteru Nagashima8Nobuteru Kubo9Tomomi Masuda10Yosuke Miura11Hiroaki Tsurumaki12Reiko Sakurai13Yasuhiko Koga14Takeshi Hisada15Toshitaka Maeno16Department of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Diagnostic Pathology Gunma University Hospital Maebashi Gunma JapanDepartment of Neurosurgery Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of General Surgical Science Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of General Surgical Science Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Radiation Oncology Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Medical Oncology Gunma University Graduate School of Medicine Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanGunma University Graduate School of Health Sciences Maebashi Gunma JapanDepartment of Respiratory Medicine Gunma University Graduate School of Medicine Maebashi Gunma JapanABSTRACT Histologic transformation from non‐small cell to small cell lung cancer (SCLC) is a resistance mechanism to immune checkpoint inhibitors. We report herein a case of lung adenocarcinoma who developed liver and brain metastases during adjuvant atezolizumab therapy. The patient underwent a craniotomy to resect a brain metastasis, which was pathologically diagnosed as SCLC. He subsequently received platinum‐based chemotherapy with durvalumab, resulting in sustained regression of the liver metastases. This case demonstrates a metastatic brain tumor‐acquired resistance to atezolizumab through histologic transformation from adenocarcinoma to SCLC. Therefore, rebiopsy is needed if recurrent disease appears during immune checkpoint inhibitor treatment in patients with non‐small cell lung cancer.https://doi.org/10.1111/1759-7714.15512adenocarcinomaimmune checkpoint inhibitornon‐small cell lung cancersmall cell lung cancertherapeutic resistance |
| spellingShingle | Nao Kobayashi Noriaki Sunaga Masakiyo Yatomi Ikuo Wakamatsu Sohei Muto Hayato Ikota Rei Yamaguchi Yoichi Ohtaki Toshiteru Nagashima Nobuteru Kubo Tomomi Masuda Yosuke Miura Hiroaki Tsurumaki Reiko Sakurai Yasuhiko Koga Takeshi Hisada Toshitaka Maeno A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy Thoracic Cancer adenocarcinoma immune checkpoint inhibitor non‐small cell lung cancer small cell lung cancer therapeutic resistance |
| title | A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy |
| title_full | A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy |
| title_fullStr | A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy |
| title_full_unstemmed | A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy |
| title_short | A Case of Primary Lung Adenocarcinoma With Recurrent Brain Metastasis due to Transformation to Small Cell Carcinoma During Adjuvant Atezolizumab Therapy |
| title_sort | case of primary lung adenocarcinoma with recurrent brain metastasis due to transformation to small cell carcinoma during adjuvant atezolizumab therapy |
| topic | adenocarcinoma immune checkpoint inhibitor non‐small cell lung cancer small cell lung cancer therapeutic resistance |
| url | https://doi.org/10.1111/1759-7714.15512 |
| work_keys_str_mv | AT naokobayashi acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT noriakisunaga acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT masakiyoyatomi acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT ikuowakamatsu acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT soheimuto acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT hayatoikota acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT reiyamaguchi acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT yoichiohtaki acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT toshiterunagashima acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT nobuterukubo acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT tomomimasuda acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT yosukemiura acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT hiroakitsurumaki acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT reikosakurai acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT yasuhikokoga acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT takeshihisada acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT toshitakamaeno acaseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT naokobayashi caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT noriakisunaga caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT masakiyoyatomi caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT ikuowakamatsu caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT soheimuto caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT hayatoikota caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT reiyamaguchi caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT yoichiohtaki caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT toshiterunagashima caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT nobuterukubo caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT tomomimasuda caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT yosukemiura caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT hiroakitsurumaki caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT reikosakurai caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT yasuhikokoga caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT takeshihisada caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy AT toshitakamaeno caseofprimarylungadenocarcinomawithrecurrentbrainmetastasisduetotransformationtosmallcellcarcinomaduringadjuvantatezolizumabtherapy |